Natera (NTRA) | Stock Overview & Key Data
Natera Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $183.00 on January 13, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Natera NTRA | 23.47B Large-cap | -3.81% | 1.01% | 16.62% | -3.48% | 0.72% | 43.48% | 299.60% | 244.76% |
| Thermo Fisher TMO | 152.45B Large-cap | 3.27% | 2.49% | -4.38% | -23.27% | -19.88% | -20.51% | -22.46% | 12.22% |
| Danaher DHR | 140.51B Large-cap | 1.06% | 0.22% | 10.52% | -16.51% | -13.13% | -15.07% | -13.10% | 24.79% |
| Idexx Laboratories IDXX | 42.13B Large-cap | 1.72% | 5.20% | 43.95% | 27.69% | 33.44% | 12.55% | 44.54% | 61.72% |
| Agilent Technologies A | 32.99B Large-cap | 1.05% | 2.15% | 15.12% | -13.22% | -10.63% | -3.95% | -0.92% | 35.74% |
| Iqvia Holdings IQV | 27.40B Large-cap | 3.08% | 5.38% | 6.17% | -19.84% | -16.74% | -21.08% | -25.12% | 15.11% |
Ownership & Short Interest
Natera Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Natera would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
In the last 52 weeks, Natera reached a high of $183.00 (on January 13, 2025) and a low of $92.14 (on August 5, 2024).
Curious about Natera's size and valuation? Its market capitalization stands at 23.47B. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -142.03.
As for dividends, Natera isn't currently offering a significant yield, or that specific data isn't available right now.
When looking at Natera, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Thermo Fisher
TMO152.45B Healthcare Diagnostics & Research -20.51% -22.46% Danaher
DHR140.51B Healthcare Diagnostics & Research -15.07% -13.10% Idexx Laboratories
IDXX42.13B Healthcare Diagnostics & Research 12.55% 44.54% Agilent Technologies
A32.99B Healthcare Diagnostics & Research -3.95% -0.92% Iqvia Holdings
IQV27.40B Healthcare Diagnostics & Research -21.08% -25.12% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
To get a sense of Natera's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -18.66%, the Debt to Equity ratio from the most recent quarter is 15.78, and its Gross Profit Margin stands at 63.12%.
Looking at Natera's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 36.50%, and quarterly earnings saw a YoY growth of N/A.
Wondering who owns Natera stock? Company insiders (like executives and directors) hold about 3.24% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 96.33%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.